Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 35
2017 80
2018 69
2019 97
2020 68
2021 16
Text availability
Article attribute
Article type
Publication date

Search Results

335 results
Results by year
Filters applied: . Clear all
Page 1
The Pharmacist's Expanding Role in HIV Pre-Exposure Prophylaxis.
Farmer EK, Koren DE, Cha A, Grossman K, Cates DW. Farmer EK, et al. AIDS Patient Care STDS. 2019 May;33(5):207-213. doi: 10.1089/apc.2018.0294. AIDS Patient Care STDS. 2019. PMID: 31067124 Review.
The efficacy of pre-exposure prophylaxis (PrEP) to prevent HIV has been firmly established; however, the success of PrEP largely depends on access to care as well as high levels of medication adherence. One of the key areas of focus for the National HIV/AIDS Strateg …
The efficacy of pre-exposure prophylaxis (PrEP) to prevent HIV has been firmly established; however, the success of PrEP largely depends on …
Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color.
Wood S, Gross R, Shea JA, Bauermeister JA, Franklin J, Petsis D, Swyryn M, Lalley-Chareczko L, Koenig HC, Dowshen N. Wood S, et al. AIDS Behav. 2019 Oct;23(10):2719-2729. doi: 10.1007/s10461-019-02502-y. AIDS Behav. 2019. PMID: 30993479 Free PMC article.
Short-term and sustained adherence were measured by urine tenofovir concentration and pharmacy refills, respectively. ...Participants completed semi-structured interviews exploring adherence barriers and facilitators. Participants (n = 31) were primarily African-Ame …
Short-term and sustained adherence were measured by urine tenofovir concentration and pharmacy refills, respectively. ...Participants …
Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data.
Byrd KK, Hou JG, Hazen R, Kirkham H, Suzuki S, Clay PG, Bush T, Camp NM, Weidle PJ, Delpino A; Patient-Centered HIV Care Model Team. Byrd KK, et al. J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):245-251. doi: 10.1097/QAI.0000000000002142. J Acquir Immune Defic Syndr. 2019. PMID: 31343455 Free PMC article.
BACKGROUND: A benchmark of near-perfect adherence (95%) to antiretroviral therapy (ART) is often cited as necessary for HIV viral suppression. ...RESULTS: The adjusted odds of viral suppression did not differ between persons with an adherence level of 80% to <85% …
BACKGROUND: A benchmark of near-perfect adherence (95%) to antiretroviral therapy (ART) is often cited as necessary for HIV viral sup …
Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review.
Pleuhs B, Quinn KG, Walsh JL, Petroll AE, John SA. Pleuhs B, et al. AIDS Patient Care STDS. 2020 Mar;34(3):111-123. doi: 10.1089/apc.2019.0189. Epub 2020 Feb 28. AIDS Patient Care STDS. 2020. PMID: 32109141 Free PMC article.
Six themes were identified across reviewed studies: (i) a lack of PrEP knowledge, (ii) the presence of the Purview Paradox, which refers to discordance in beliefs between HIV specialists and primary care providers on who should prescribe PrEP, (iii) concerns about PrEP costs, (iv …
Six themes were identified across reviewed studies: (i) a lack of PrEP knowledge, (ii) the presence of the Purview Paradox, which refers to …
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ. Landovitz RJ, et al. PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov. PLoS Med. 2018. PMID: 30408115 Free PMC article. Clinical Trial.
One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test. ...The safety and pharmacokinetic results obs …
One HIV infection occurred in a participant 48 weeks after last injection of CAB LA: CAB was not detectable in plasma both at the time
Screening for HIV Infection: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. US Preventive Services Task Force, et al. JAMA. 2019 Jun 18;321(23):2326-2336. doi: 10.1001/jama.2019.6587. JAMA. 2019. PMID: 31184701
The USPSTF found convincing evidence that identification and early treatment of HIV infection is of substantial benefit in reducing the risk of AIDS-related events or death. ...The USPSTF also found convincing evidence that identification and treatment of pre …
The USPSTF found convincing evidence that identification and early treatment of HIV infection is of substantial benefit in reducing t …
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. US Preventive Services Task Force, et al. JAMA. 2019 Jun 11;321(22):2203-2213. doi: 10.1001/jama.2019.6390. JAMA. 2019. PMID: 31184747
EVIDENCE REVIEW: The USPSTF reviewed the evidence on the benefits of PrEP for the prevention of HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whether the benefits vary by risk group, population su …
EVIDENCE REVIEW: The USPSTF reviewed the evidence on the benefits of PrEP for the prevention of HIV infection with oral tenofovir disoproxil …
Clinical characteristics and treatment patterns among US patients with HIV.
Priest JL, Burton T, Blauer-Peterson C, Andrade K, Oglesby A. Priest JL, et al. Am J Manag Care. 2019 Dec;25(12):580-586. Am J Manag Care. 2019. PMID: 31860226 Free article.
OBJECTIVES: Describe the clinical characteristics and treatment patterns of patients with HIV-1 who have commercial or Medicare health insurance in the United States. ...Overall, 60% of patients achieved 90% or greater adherence to their ART regimen and 16% had a pr …
OBJECTIVES: Describe the clinical characteristics and treatment patterns of patients with HIV-1 who have commercial or Medicare healt …
Test-and-treat approach to HIV/AIDS: a primer for mathematical modeling.
Nah K, Nishiura H, Tsuchiya N, Sun X, Asai Y, Imamura A. Nah K, et al. Theor Biol Med Model. 2017 Sep 5;14(1):16. doi: 10.1186/s12976-017-0062-9. Theor Biol Med Model. 2017. PMID: 28870213 Free PMC article. Review.
The public benefit of test-and-treat has induced a need to justify goodness for the public, and mathematical modeling studies have played a key role in designing and evaluating the test-and-treat strategy for controlling HIV/AIDS. Here we briefly and comprehensively review …
The public benefit of test-and-treat has induced a need to justify goodness for the public, and mathematical modeling studies have played a …
335 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page